Patients Recieving Anti-PD-1 or Anti-PD-L1 Immunotherapies
Conditions
Brief summary
The primary objective of this study is to determine the impact of anti-checkpoint immunotherapy on type 2 inflammation via a retrospective analysis of % eosinophilia.
Interventions
Immunotherapy treatment via anti programmed death 1 and/or anti-programmed death ligand 1.
Sponsors
University Hospital, Montpellier
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Electronic patient file DxCare at the University Hospitals of Montpellier * Patient has received anti-PD-1 immunotherapy --AND/OR -- anti-PD-L1 immunotherapy according to central pharmacy records
Exclusion criteria
* No mention of % eosinophilia in the patient file
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in % eosinophilia after initiation of anti-PD-1 and/or anti-PD-L1 | Before treatment (before day 0) versus after (15 days) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Indication leading to anti-PD-1 and/or anti-PD-L1 immunotherapies | Day 0 | Name of pathology |
| Age (years) | Day 0 | — |
| Sex (male/female) | Day 0 | — |
Countries
France
Outcome results
None listed